SI9520083A - Triazole compounds and their use as dopamine-d3-ligands - Google Patents

Triazole compounds and their use as dopamine-d3-ligands Download PDF

Info

Publication number
SI9520083A
SI9520083A SI9520083A SI9520083A SI9520083A SI 9520083 A SI9520083 A SI 9520083A SI 9520083 A SI9520083 A SI 9520083A SI 9520083 A SI9520083 A SI 9520083A SI 9520083 A SI9520083 A SI 9520083A
Authority
SI
Slovenia
Prior art keywords
alkyl
stands
halogen
formula
optionally substituted
Prior art date
Application number
SI9520083A
Other languages
English (en)
Slovenian (sl)
Inventor
Beate Hellendahl
Annegret Lansky
Rainer Munschauer
Siegfried Bialojan
Liliane Unger
Hans-Juergen Teschendorf
Karsten Wicke
Karla Drescher
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6523323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI9520083(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Basf Ag filed Critical Basf Ag
Publication of SI9520083A publication Critical patent/SI9520083A/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI9520083A 1994-07-15 1995-07-14 Triazole compounds and their use as dopamine-d3-ligands SI9520083A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4425144A DE4425144A1 (de) 1994-07-15 1994-07-15 Triazolverbindungen und deren Verwendung
PCT/EP1995/002781 WO1996002520A1 (de) 1994-07-15 1995-07-14 Triazolverbindungen und deren verwendung als dopamin-d3-liganden

Publications (1)

Publication Number Publication Date
SI9520083A true SI9520083A (en) 1997-10-31

Family

ID=6523323

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9520083A SI9520083A (en) 1994-07-15 1995-07-14 Triazole compounds and their use as dopamine-d3-ligands

Country Status (23)

Country Link
US (1) US6124294A (ru)
EP (1) EP0772604B1 (ru)
KR (1) KR100379196B1 (ru)
CN (1) CN1068314C (ru)
AT (1) ATE179703T1 (ru)
AU (1) AU703889B2 (ru)
BG (1) BG63500B1 (ru)
BR (1) BR9508294A (ru)
CA (1) CA2195243C (ru)
CZ (1) CZ292625B6 (ru)
DE (2) DE4425144A1 (ru)
DK (1) DK0772604T3 (ru)
ES (1) ES2131842T3 (ru)
FI (1) FI970147A0 (ru)
GR (1) GR3030371T3 (ru)
HU (1) HU225961B1 (ru)
IL (1) IL114598A (ru)
NO (1) NO315320B1 (ru)
NZ (1) NZ290387A (ru)
RU (1) RU2167869C2 (ru)
SI (1) SI9520083A (ru)
WO (1) WO1996002520A1 (ru)
ZA (1) ZA955867B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19600934A1 (de) 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
DE19728996A1 (de) 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
CO5140073A1 (es) 1998-10-08 2002-03-22 Smithkline Beecham Plc Derivados de 2,3,4,5-tetrahidro-1h-3-benzapina
TWI274750B (en) * 1999-01-12 2007-03-01 Abbott Gmbh & Co Kg Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same
AU7989400A (en) 1999-10-01 2001-05-10 Smithkline Beecham Corporation Compounds and methods
ES2311012T3 (es) * 2000-03-27 2009-02-01 ABBOTT GMBH & CO. KG Ligandos del receptor d3 de la dopamina para el tratamiento de la adiccion.
DE10109867A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10109866A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
CA2498936C (en) 2002-09-14 2013-02-12 Gov't Of The Usa As Represented By The Secretary Of The Department Of Health & Human Services Structurally rigid dopamine d3 receptor selective ligands and process for making them
CZ300500B6 (cs) * 2002-11-11 2009-06-03 Zpusob uzavírání špic v pletacím stroji
DE10304870A1 (de) * 2003-02-06 2004-08-19 Abbott Gmbh & Co. Kg Triazolverbindungen und ihre therapeutische Verwendung
JP2004359689A (ja) * 2003-06-05 2004-12-24 Abbott Gmbh & Co Kg ドーパミンd3受容体のモジュレーションに反応する障害の治療に適するトリアゾール化合物
US6919342B2 (en) 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
DE10358004A1 (de) 2003-12-11 2005-07-14 Abbott Gmbh & Co. Kg Ketolactam-Verbindungen und ihre Verwendung
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
CA2550053C (en) 2003-12-18 2013-01-22 Abbott Gmbh & Co. Kg Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
ATE452134T1 (de) * 2004-08-09 2010-01-15 Abbott Gmbh & Co Kg Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen
JP5049134B2 (ja) * 2004-12-02 2012-10-17 アボット ゲーエムベーハー ウント カンパニー カーゲー ドーパミンd3受容体の調節に応答する障害の治療に好適なトリアゾール化合物
GB0507680D0 (en) 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
WO2009019472A1 (en) 2007-08-07 2009-02-12 Prosarix Limited 1, 2, 4 -triazole derivatives as serotonergic modulators
PA8802101A1 (es) 2007-11-02 2009-08-26 Abbott Gmbh & Co Kg Compuestos de 1,2,4-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3
HUE031419T2 (en) * 2008-07-03 2017-07-28 Astellas Pharma Inc Triazole derivative or salt

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1053085A (ru) * 1964-03-26
US4408049A (en) * 1980-09-17 1983-10-04 The Upjohn Company Substituted piperazinyl-1,2,4-triazoles
US4338453A (en) * 1980-09-17 1982-07-06 The Upjohn Company Aminoalkyl-1,2,4-triazoles
US4487773A (en) * 1981-03-16 1984-12-11 Mead Johnson & Company 1,2,4-Triazol-3-one antidepressants
US4577020A (en) * 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
US4575555A (en) * 1983-06-29 1986-03-11 Mead Johnson & Company 4-(3-Chlorophenyl)-1,2,3,6-tetrahydropyridine derivative
US4613600A (en) * 1983-09-30 1986-09-23 Mead Johnson & Company Antidepressant 1,2,4-triazolone compounds
FR2580648B1 (fr) * 1985-04-17 1987-05-15 Adir Nouveaux derives du triazole, leur procede de preparation et les compositions pharmaceutiques les renfermant
FR2601952B1 (fr) * 1986-07-23 1988-11-25 Carpibem Nouveaux derives amino alkyl thio de triazolopyridine ou triazoloquinoline, leurs procedes de preparation, medicaments les contenant, utiles notamment comme antalgiques
FR2672052B1 (fr) * 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
GB9021535D0 (en) * 1990-10-03 1990-11-14 Wyeth John & Brother Ltd Piperazine derivatives
US5256664A (en) * 1992-04-28 1993-10-26 Bristol-Myers Squibb Company Antidepressant 3-halophenylpiperazinylpropyl derivatives of substituted triazolones and triazoldiones

Also Published As

Publication number Publication date
NZ290387A (en) 1999-02-25
AU3111395A (en) 1996-02-16
FI970147A (fi) 1997-01-14
CA2195243A1 (en) 1996-02-01
JP4114950B2 (ja) 2008-07-09
ATE179703T1 (de) 1999-05-15
BR9508294A (pt) 1997-12-30
KR100379196B1 (ko) 2003-06-11
US6124294A (en) 2000-09-26
CA2195243C (en) 2006-05-30
HU225961B1 (en) 2008-01-28
EP0772604B1 (de) 1999-05-06
ES2131842T3 (es) 1999-08-01
BG101113A (en) 1998-04-30
BG63500B1 (bg) 2002-03-29
WO1996002520A1 (de) 1996-02-01
DE4425144A1 (de) 1996-01-18
EP0772604A1 (de) 1997-05-14
KR970704710A (ko) 1997-09-06
FI970147A0 (fi) 1997-01-14
JPH10502914A (ja) 1998-03-17
NO315320B1 (no) 2003-08-18
IL114598A (en) 1999-12-22
CZ9797A3 (en) 1997-08-13
CZ292625B6 (cs) 2003-11-12
DK0772604T3 (da) 1999-11-01
HU9700109D0 (en) 1997-02-28
RU2167869C2 (ru) 2001-05-27
HUT77128A (hu) 1998-03-02
DE59505853D1 (de) 1999-06-10
AU703889B2 (en) 1999-04-01
CN1152919A (zh) 1997-06-25
NO970161L (no) 1997-03-14
ZA955867B (en) 1997-01-14
IL114598A0 (en) 1995-11-27
NO970161D0 (no) 1997-01-14
GR3030371T3 (en) 1999-09-30
CN1068314C (zh) 2001-07-11

Similar Documents

Publication Publication Date Title
SI9520083A (en) Triazole compounds and their use as dopamine-d3-ligands
US6342604B1 (en) Substitute pyrimidine compounds and the use thereof
KR100441073B1 (ko) 치환된아자-및디아자시클로헵탄및시클로옥탄화합물및그의용도
KR100443216B1 (ko) D₃도파민수용체리간드로유용한티아디아졸화합물
US6472392B1 (en) Triazole compounds and the use thereof as dopamine-D3 -ligands
KR100443850B1 (ko) 헤테로시클릭 화합물의 도파민-d3 리간드로서의 용도
US8101754B2 (en) Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
US6403593B1 (en) Triazole compounds and the use thereof
JP4114950B6 (ja) トリアゾール化合物及び該化合物の使用
RU2172736C2 (ru) Соединение пиримидина(варианты) и фармацевтическая композиция, обладающая сродством к допамин d3-рецепторам
MXPA97000124A (en) Triazol compounds and the use of mis

Legal Events

Date Code Title Description
IF Valid on the event date
SP73 Change of data on owner

Owner name: ABBVIE DEUTSCHLAND GMBH & CO. KG; DE

Effective date: 20140307